Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss
Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Oct 20, 2016
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 years old to menopause
- • polycystic ovary syndrome (NICHD criteria)
- • BMI of 30kg/m2 or higher
- Exclusion Criteria:
- • type 1 or type 2 diabetes mellitus
- • history of carcinoma
- • Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
- • personal or family history of multiple endocrine neoplasia type 2
- • significant cardiovascular, kidney or hepatic disease
- • the use of statins, within 90 days prior to study entry
About University Medical Centre Ljubljana
University Medical Centre Ljubljana (UMCL) is a leading academic medical institution in Slovenia, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMCL integrates cutting-edge medical practices with comprehensive patient care, fostering an environment of collaboration among healthcare professionals, researchers, and patients. With a strong emphasis on ethical standards and scientific integrity, UMCL aims to contribute to the global body of medical knowledge while improving treatment outcomes in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Andrej Janež, MD PhD
Principal Investigator
University Medical Centre Ljubljana
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials